AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06549712 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: identify genetic determinants of the predisposition to develop respiratory failure
Description: To provide extensive genetic characterization of all patients managed at the Fondazione in order to facilitate other groups working on specific projects (e.g. on candidate genes such as SERPINA1 and ACE2 by the Intensive Care and Cardiology Units and other that may emerge from upcoming projects), in a large population and in a very timely fashion, and without incurring in any additional expenses for the Fondazione research network, and coordinate research efforts.
Study NCT06549712 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: identify genetic determinants of the predisposition to develop respiratory failure
Description: To provide a coordination to manage the collaboration with other research consortia in the field, e.g. the An anonymized GWAS to urgently query host genetic predisposition to severe COVID-19 (SARS-CoV-2 infection) lung disease, and the COVID-19 Host Genetic Initiative (https://www.covid19hg.org). Indeed, collaboration among large networks analyzing several thousand cases will be ultimately necessary to clarify the genetic basis of COVID-19 susceptibility, and large collaborative networks are essential instruments for conducting human genetic research.
Study NCT01867983 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight gain prevention and smoking cessation
Description: The two intervention groups will receive weight gain prevention either:~Simultaneous: weight control treatment simultaneous with cessation treatment (5 proactive calls with a quit coach combined with weight coach/nutritionist followed by 5 'contact control calls'), or Sequential: weight control treatment added after cessation treatment (5 proactive calls with a quit coach followed by 5 weight coach/nutritionist calls). All three study arms will include a total of 10 phone counseling calls, interactive web, mailed support materials, access to nicotine replacement therapy (NRT) and unlimited participant initiated calls.
Study NCT04294615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FMT through a naso-jejunal tube
Description: Prepared feces by automatic methods, then the purified fecal microbiota was delivered into the intestine through a naso-jejunal tube.
Study NCT04294615 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FMT through TET
Description: Prepared feces by automatic methods, then the purified fecal microbiota was delivered into the intestine through a transendoscopic enteral tubing (TET) which is fixed to the cecum with clips under endoscopic guidance.
Study NCT02777606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Si-Ni-Tang
Description: Treatment adheres to the International guidelines for management of severe sepsis and septic shock( 2012) and the Surviving Sepsis Campaign updated bundles in response to new evidence in 2015 for both the treatment group and the control group. In addition, 150ml of Si-Ni-Tang will be given by p.o. or by a nasogastric tube once a day for 3 days in the treatment group.
Study NCT02030197 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CRISP Program
Description: Educational program to improve self-efficacy, loneliness and depression
Study NCT02030197 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: no treatment
Study NCT01335724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac diethylamine 1.16% gel
Description: Diclofenac diethylamine 1.16% gel
Study NCT01335724 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Placebo gel
Study NCT03899155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days
Study NCT02793817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KPI-121 1% Ophthalmic Suspension dosed BID
Study NCT02793817 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle of KPI-121 Ophthalmic Suspension dosed BID
Study NCT02499900 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Copaxone®
Description: Subcutaneous Injections
Study NCT02499900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copaxone®
Description: Subcutaneous Injections
Study NCT04135560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07038124 and Vehicle
Description: PF-07038124 0.06% and vehicle Ointment BID applied to 1% Body Surface Area (BSA)
Study NCT04135560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07038124 or vehicle
Description: PF-07038124 0.01% or vehicle Ointment QD applied to 10% BSA
Study NCT04135560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07038124 or vehicle
Description: PF-07038124 0.01% or vehicle Ointment BID applied to 10% BSA
Study NCT03899155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Specified dose on specified days
Study NCT03899155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Specified dose on specified days
Study NCT03899155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Specified dose on specified days
Study NCT04135560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07038124 or vehicle
Description: PF-07038124 0.03% or vehicle Ointment BID applied to 10% BSA
Study NCT04135560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07038124 or vehicle
Description: PF-07038124 0.06% or vehicle ointment BID applied to 10% BSA
Study NCT03899155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab + Relatlimab
Description: Specified dose on specified days
Study NCT03899155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Specified dose on specified days
Study NCT03899155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Specified dose on specified days
Study NCT01867983 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking cessation
Description: The control group will receive cessation treatment calls (5 proactive calls with a quit coach followed by 5 contact control calls.
Study NCT03899155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Specified dose on specified days
Study NCT03899155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Specified dose on specified days
Study NCT03899155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Specified dose on specified days
Study NCT03899155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafinib
Description: Specified dose on specified days
Study NCT03899155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Specified dose on specified days
Study NCT03899155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Specified dose on specified days
Study NCT03899155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Specified dose on specified days
Study NCT03899155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Specified dose on specified days
Study NCT03899155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Specified dose on specified days
Study NCT03899155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Specified dose on specified days
Study NCT03899155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Specified dose on specified days
Study NCT03762915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: minocycline HCl microspheres
Description: Minocycline HCl microspheres, 1 mg are approved by the Food and Drug Administration (FDA) as an adjunct to SRP procedures for reduction of pocket depth in patients with adult periodontitis.
Study NCT04063215 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HB-adMSCs
Description: Hope Biosciences autologous adipose-derived mesenchymal stem cells
Study NCT03460080 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: AFP-L3 and PIVKA-II in HCC
Description: Serum samples are tested for tumor markers including PIVKA-II, AFP, AFP-L3% and biochemical tests.~Imaging: CT or MRI
Study NCT04135560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07038124 or vehicle
Description: PF-07038124 safe concentration or vehicle ointment BID applied to 20% BSA
Study NCT04135560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07038124 or vehicle
Description: PF-07038124 safe concentration or vehicle BID applied to 10% BSA
Study NCT04953819 — intervention group
Intervention type: OTHER
Intervention: Revascularization
Description: Percutaneous coronary intervention and/or coronary bypass grafting for coronary artery disease
Study NCT04953819 — intervention group
Intervention type: OTHER
Intervention: Medical therapy
Description: Optimal medical therapy for coronary artery disease
Study NCT03762889 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eyeprotx™ General Anesthesia Protective Goggles
Description: Eyeprotx™ Protective Goggles have been designed specifically for use in the operating room or in any scenario where general anesthesia must be used, such as intubation in an emergency. The integral function is to reduce intraocular pressure while in place, prevent operating room bright light penetration, facilitate a swift placement preventative measure with straps, form a barrier against bacterial invasion and mechanical damage. This study would seek to examine this goggles' effectiveness as a preventative measure as vs. other measures.
Study NCT03762889 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eyelid Tape
Description: Taping the eyelids during intubation is one of the standard techniques used perioperatively under general anesthesia. This intervention would be used for the Eyelid Tape Group.
Study NCT03762889 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eye Ointment
Description: Another standard technique used perioperatively under general anesthesia is to apply an ointment to the eye for lubrication. This intervention would be applied to the Eye Ointment Group.
Study NCT03983265 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Bilateral Sagittal Split Osteotomy
Description: after BSSO condyle will be re positioned by using computer guided device
Study NCT02374814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabies vaccine
Description: Compare dose schedule and route of administration
Study NCT02374814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabies vaccine
Description: Compare dose schedule and route of administration
Study NCT02374814 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02052726 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C. difficile vaccine with adjuvant
Description: C. difficile vaccine with adjuvant administered at Month 0, 1, and 3.
Study NCT02052726 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered at Month 0, 1, and 3.
Study NCT02052726 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C. difficile vaccine with adjuvant
Description: C. difficile vaccine with adjuvant administered at day 1, 8, 30.
Study NCT02052726 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo administered at Day 1, 8, and 30.
Study NCT03074292 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: phototherapy
Description: estimate oxidative stress and trace elements in neonates with unconjugated hyperbilirubinemia after exposure to phototherapy
Study NCT04627675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORVax
Description: DNA-encodable coronaviral vaccine
Study NCT04627675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-12 plasmid
Description: cytokine
Study NCT04627675 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cliniporator
Description: electroporation system
Study NCT04559022 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fat Grafting
Description: This single-center, clinical trial will assess the efficacy and tolerability of the autologous fat grafting when used on men and women with acne scars on the face.
Study NCT03430843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200 mg administered intravenously (IV)
Study NCT03430843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 135-175 mg /m² administered IV , or 80-100 mg/m\^2 administered IV according to local guidelines for standard of care
Study NCT03430843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75 mg/m\^2 administered IV or 70 mg/m\^2 IV in Japan
Study NCT03430843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: 125 mg/m\^2 administered IV
Study NCT03988985 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GP-targeted feedback
Description: The feedback for the general practitioner contains the screening result and guideline-based recommendations, i.e. to inform patients of their depression screening result. Nevertheless, in order to reflect routine clinical practice, the physicians will decide themselves whether or not to address depression during their consultation with the patient.
Study NCT03988985 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GP-targeted feedback
Description: The feedback for the general practitioner contains the screening result and guideline-based recommendations, i.e. to inform patients of their depression screening result. Nevertheless, in order to reflect routine clinical practice, the physicians will decide themselves whether or not to address depression during their consultation with the patient.
Study NCT02321644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90001
Description: CC-90001 Active-ingredient-in-capsule and formulated tablet
Study NCT05862454 — intervention group
Intervention type: DRUG
Intervention: Magnesium
Description: Magnesium injection therapy
Study NCT03691857 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasound algorithm (EMERALD-US)
Description: Ultrasound algorithm EMERALD-US is an dedicated to emergencies using lung, cardiac and vascular ultrasound for the 3 main dyspnea causes (heart failure, pneumonia and obstructive pulmonary disease exacerbation) in patients with acute non-traumatic dyspnea managed in the emergency department. The ultrasounds will be performed within first hour after first medical contact in emergency department by another emergency physician not in charge of the patient. The ultrasound results will be not shared with the emergency physician in charge of the patient.
Study NCT03651505 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Access to any treatment is through authorized commercial use and not as a part of this DMP
Study NCT04522817 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CLBS119
Description: Peripheral blood derived autologous CD34+ cells
Study NCT01192763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Description: Given orally
Study NCT02679144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Difluoromethylornithine (DFMO)
Description: Subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study.
Study NCT04493424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: Spesolimab
Study NCT02551094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: colchicine
Description: 0.5 mg tablet taken once a day
Study NCT01192763 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01192763 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01192763 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Study NCT02551094 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: colchicine placebo
Description: sugar pill manufactured to mimic colchicine 0.5 mg tablet
Study NCT02920528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: sub-dissociative ketamine
Study NCT02920528 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline
Study NCT02079116 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 60 grams of fat plus water solution
Description: A solution composed by 60 grams of fat and water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~* 300 mL final volume of the solution.~* Time of oral ingestion inferior than 2 minutes.~* 60 minutes before the radiopharmaceutical injection.~* 12 hours fasting minimum.
Study NCT02079116 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 60 grams of fat plus water solution
Description: A solution composed by 60 grams of fat and water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~* 300 mL final volume of the solution.~* Time of oral ingestion inferior than 2 minutes.~* 60 minutes before the radiopharmaceutical injection.~* 12 hours fasting minimum.
Study NCT02079116 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pure water
Description: Pure water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~* 300 mL final volume of the solution.~* Time of oral ingestion inferior than 2 minutes.~* 30 minutes before the radiopharmaceutical injection.~* 12 hours fasting minimum.
Study NCT02079116 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pure water
Description: Pure water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~* 300 mL final volume of the solution.~* Time of oral ingestion inferior than 2 minutes.~* 30 minutes before the radiopharmaceutical injection.~* 12 hours fasting minimum.
Study NCT01192763 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Study NCT03092986 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: paclitaxel 200 mg/m2 i.v over 3 hrs on day 1, every 21 days for 2 cycles followed by radiotherapy on day 42
Study NCT04318223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Patients will be enrolled into the study and assign to receive Palbociclib 125 mg/day orally for 3 weeks followed by 1 week off plus fulvestrant 500 mg intramuscularly on Days 1 and 15 of Cycle 1, every 28 days (+/- 7 days) thereafter starting from Day 1 of Cycle 1
Study NCT02186834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor orally as outlined in the study treatment arm.
Study NCT03092986 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: carboplatin AUC 6 iv over 1 hr on day 1 , every 212 days for 2 cycle followed by radiotherapy on day 42
Study NCT03092986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: cisplatin 100 mg/m2 i.v over 2 hrs on day 1 and 29 followed by radiotherapy on day 50
Study NCT03092986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine Sulfate
Description: Vinblastin 5mg/m2 i.v on day 1,8,15,22 and 29 followed by radiotherapy on day 50
Study NCT03092986 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: three dimensional conformal radiotherapy
Description: three dimensional conformal radiotherapy would be given at day 42 after completion of paclitaxel and carboplatin 2 cycle and at day 50 after completion of cisplatin and vinblastin from d1 to d29
Study NCT03092986 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: three dimensional conformal radiotherapy
Description: three dimensional conformal radiotherapy would be given at day 42 after completion of paclitaxel and carboplatin 2 cycle and at day 50 after completion of cisplatin and vinblastin from d1 to d29
Study NCT00093197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAI-9803 for Injection
Description: 0.05 mg
Study NCT00093197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAI-9803 for Injection
Description: 0.5 mg
Study NCT00093197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAI-9803 for Injection
Description: 1.25 mg
Study NCT00093197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAI-9803 for Injection
Description: 5 mg
Study NCT00093197 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo